EA5181

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Contact phone
Clinical Trials Office – 517-364-9402
Principal investigator
Gordan Srkalovic, M.D., PhD
Trial Category
Cancer
Trial SubCategory
Lung